Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, Chen SS, McColl D, Holmes CB, Enejosa J, Toole JJ, Cheng AK.
Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis.
J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):74-78.
PMID: 17971715 [PubMed - as supplied by publisher]
Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Clin Infect Dis. 2007 Aug 1;45(3):381-90. Epub 2007 Jun 26.
PMID: 17599319 [PubMed - indexed for MEDLINE]
Nelson MR, Katlama C, Montaner JS, Cooper DA, Gazzard B, Clotet B, Lazzarin A, Schewe K, Lange J, Wyatt C, Curtis S, Chen SS, Smith S, Bischofberger N, Rooney JF.
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS. 2007 Jun 19;21(10):1273-81.
PMID: 17545703 [PubMed - indexed for MEDLINE]
Hardy GA, Imami N, Nelson MR, Sullivan AK, Moss R, Aasa-Chapman MM, Gazzard B, Gotch FM.
A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.
J Immune Based Ther Vaccines. 2007 Apr 11;5:6.
PMID: 17428345 [PubMed]
ESPRIT Research Group, Fox Z, Antunes F, Davey R, Gazzard B, Klimas N, Labriola A, Losso M, Neaton JD, Phillips AN, Ruxrungtham K, Staszewski S, Weiss L, Lundgren JD.
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.
HIV Med. 2007 Mar;8(2):112-23.
PMID: 17352768 [PubMed - indexed for MEDLINE]
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C.
CD4+ count-guided interruption of antiretroviral treatment.
N Engl J Med. 2006 Nov 30;355(22):2283-96.
PMID: 17135583 [PubMed - indexed for MEDLINE]
Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, Chen SS, McColl D, Enejosa J, Toole JJ, Cheng AK.
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40.
PMID: 17057609 [PubMed - indexed for MEDLINE]
Moyle G, Fletcher C, Brown H, Mandalia S, Gazzard B.
Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen.
HIV Med. 2006 May;7(4):243-7.
PMID: 16630036 [PubMed - indexed for MEDLINE]
Moyle G, Higgs C, Teague A, Mandalia S, Nelson M, Johnson M, Fisher M, Gazzard B.
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Antivir Ther. 2006;11(1):73-8.
PMID: 16518962 [PubMed - indexed for MEDLINE]
Gold J, Batterham MJ, Rekers H, Harms MK, Geurts TB, Helmyr PM, Silva de Mendonça J, Falleiros Carvalho LH, Panos G, Pinchera A, Aiuti F, Lee C, Horban A, Gatell J, Phanuphak P, Prasithsirikul W, Gazzard B, Bloch M, Danner SA; E-1696 Study Investigators.
Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting.
HIV Med. 2006 Apr;7(3):146-55.
PMID: 16494628 [PubMed - indexed for MEDLINE]
Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK; Study 934 Group.
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.N Engl J Med. 2006 Jan 19;354(3):251-60.
PMID: 16421366 [PubMed - indexed for MEDLINE]
Dragsted UB, Gerstoft J, Youle M, Fox Z, Losso M, Benetucci J, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Gazzard B, Walmsley S, Hill A, Lundgren JD; MaxCmin2 Trial Group.
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial.
Antivir Ther. 2005;10(6):735-43.
PMID: 16218173 [PubMed - indexed for MEDLINE]
Smith CJ, Phillips AN, Hill T, Fisher M, Gazzard B, Porter K, Gilson R, Easterbrook P, Matthias R, Scullard G, Johnson MA, Sabin CA; United Kingdom Collaborative HIV Cohort Study Group.
The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study.
J Infect Dis. 2005 Oct 15;192(8):1387-97. Epub 2005 Sep 14.
PMID: 16170756 [PubMed - indexed for MEDLINE]
Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, Gazzard BG, Nelson MR. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin.
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):41-6.
PMID: 16123680 [PubMed - indexed for MEDLINE]
Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK.
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
AIDS. 2006 Oct 24;20(16):2043-50.
Maitland D, Moyle G, Hand J, Mandalia S, Boffito M, Nelson M, Gazzard B.
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
AIDS. 2005 Jul 22;19(11):1183-8.
PMID: 15990571 [PubMed - indexed for MEDLINE]
Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ.
Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.
HIV Med. 2005 May;6(3):185-90.
PMID: 15876285 [PubMed - indexed for MEDLINE]
Sabin CA, Hill T, Lampe F, Matthias R, Bhagani S, Gilson R, Youle MS, Johnson MA, Fisher M, Scullard G, Easterbrook P, Gazzard B, Phillips AN; UK Collaborative HIV Cohort (UK CHIC) Study Group.
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
BMJ. 2005 Mar 26;330(7493):695. Epub 2005 Mar 4.
PMID: 15749728 [PubMed - indexed for MEDLINE]
Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, Jones R, Moyle G, Fisher M, Gazzard B.
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
J Antimicrob Chemother. 2005 Feb;55(2):246-51. Epub 2004 Dec 17.
PMID: 15608053 [PubMed - indexed for MEDLINE]
Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, Rockstroh J, Stoehr A, Vetter N, Yeni P, Parys W, Vangeneugden T; the POWER 1 study group.
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
AIDS. 2007 Feb 19;21(4):395-402.
Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Béthune MP, Peeters M, Woodfall B.
Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
AIDS. 2006 Aug 22;20(13):1721-6.
Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, James IT, Jenkins TM, Perros M, van der Ryst E.
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
J Virol. 2006 May;80(10):4909-20
Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E.
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Nat Med. 2005 Nov;11(11):1170-2. Epub 2005 Oct 5.
Arastéh K, Clumeck N, Pozniak A, Lazzarin A, De Meyer S, Muller H, Peeters M, Rinehart A, Lefebvre E; TMC114-C207 Study Team.
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.
AIDS. 2005 Jun 10;19(9):943-7.
Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK; 903 Study Group.
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
JAMA. 2004 Jul 14;292(2):191-201.